News & Updates
Filter by Specialty:
COVID-19 vaccine booster efficacy: What do new HK data show?
A booster dose of the mRNA-based BNT162b2 vaccine provides more robust antibody responses to SARS-CoV-2, including the Omicron BA.1 and BA.2 variants, than the inactivated CZ02 vaccine, but three doses of either vaccine are equally effective in reducing the risk of severe or fatal COVID-19, according to new local data presented at the 26th Hong Kong Medical Forum (HKMF).
COVID-19 vaccine booster efficacy: What do new HK data show?
23 May 2022
Male sex, obesity among risk factors for severe COVID-19 in children
A large study by the US National COVID Cohort Collaborative (N3C) has identified factors associated with the risk of severe disease among children with SARS-CoV-2 infection as well as factors tied to an increased risk of multisystem inflammatory syndrome in children (MIS-C) as compared to acute COVID-19.
Male sex, obesity among risk factors for severe COVID-19 in children
20 May 2022
No apparent link between COVID-19 vax and cerebrovascular outcomes
Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.
No apparent link between COVID-19 vax and cerebrovascular outcomes
13 May 2022
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
10 May 2022
First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC
Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.